Haier Biomedical Reports Record 36% International Revenue Growth in Life Science Infrastructure Market

Key Takeaways

• Haier Biomedical reported $340.77 million in total revenue for 2025, with international business reaching a record 36% share
• Overseas revenue grew 17.9% year-over-year to $122.68 million, demonstrating strong global expansion in life science infrastructure
• Company transitions from product coverage to premium brand leadership through AI-powered intelligent productivity platforms

---

QINGDAO, China - Haier Biomedical (688139.SH) reported record-breaking international performance in its 2025 annual results, with overseas revenue comprising 36% of total annual revenue for the first time in company history.

The life sciences and medical solutions leader posted full-year revenue of 2.33 billion yuan ($340.77 million), with international business growing 17.9% year-over-year to 840 million yuan ($122.68 million). This milestone represents a significant shift in the company’s revenue composition, highlighting successful global market penetration.

AI-Powered Growth Strategy

Haier Biomedical’s expansion strategy centers on artificial intelligence integration across its life science infrastructure portfolio. The company has evolved from traditional product coverage to establishing itself as a premium brand leader in intelligent productivity platforms for laboratories and medical facilities worldwide.

The strong international performance reflects growing global demand for advanced life science tools and infrastructure, particularly in emerging markets across the Asia-Pacific region. Healthcare systems worldwide are increasingly investing in modernized laboratory equipment and AI-enhanced medical technologies.

Market Impact and Industry Position

The revenue milestone positions Haier Biomedical as a significant player in the global life sciences equipment market, which has experienced accelerated growth following increased healthcare infrastructure investments post-pandemic. The company’s focus on intelligent productivity platforms aligns with industry trends toward automation and data-driven laboratory operations.

Industry analysts note that the 36% international revenue share demonstrates successful diversification beyond domestic markets, reducing geographic concentration risk while capitalizing on global healthcare modernization initiatives.

Future Outlook

Haier Biomedical’s transformation into a global life science tools platform provider reflects broader industry consolidation and technological advancement. The company’s AI-powered solutions address critical needs in laboratory efficiency, data management, and operational optimization across international markets.

The strong 2025 performance establishes a foundation for continued international expansion, with the company well-positioned to capture additional market share in the growing global life sciences infrastructure sector.

---

Frequently Asked Questions

What does Haier Biomedical’s international growth mean for global healthcare?

The 36% international revenue share indicates successful expansion of advanced life science infrastructure globally, bringing AI-powered laboratory solutions to more healthcare systems worldwide and improving research capabilities.

How significant is the 17.9% overseas revenue growth?

This growth rate substantially outpaces typical industry expansion, demonstrating strong market demand for Haier Biomedical’s intelligent productivity platforms and positioning the company as a major global competitor in life sciences equipment.

What makes Haier Biomedical’s AI-powered approach different from competitors?

Haier Biomedical has transitioned from traditional product sales to comprehensive intelligent productivity platforms, integrating AI across laboratory operations to enhance efficiency, data management, and operational optimization for life science facilities.